Brauner et al. found that combining the BRAF inhibitor and anti-PD-L1 antibody markedly improved tumor immunity (e.g., CD8+ cell infiltration and CD8+: Treg ratio) and tumor regression in an immunocompetent murine model of ATC. Here, CD8A is linked to neoplasm.